Next 10 |
Combined company operating as Cyclo Therapeutics with primary focus on advancing Trappsol ® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 (NPC1) Cash runway extended into 2H 2024 with approximately $11.0 million cash on hand to fund operations Cyclo ...
2023-11-09 17:41:32 ET More on Applied Molecular Transport Applied Molecular to merge with Cyclo Therapeutics in all-stock deal Seeking Alpha’s Quant Rating on Applied Molecular Transport Historical earnings data for Applied Molecular Transport Financi...
Company Entered into Definitive Merger Agreement with Cyclo Therapeutics Cash and Cash Equivalents of $18.1 million, as of September 30, 2023 SOUTH SAN FRANCISCO, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a biopharmaceut...
CGG ADR (CGGYY) is expected to report for quarter end 2023-09-30 ATI Physical Therapy Inc. Class A (ATIP) is expected to report $-4.08 for Q3 2023 Riot Platforms Inc. (RIOT) is expected to report $-0.29 for Q3 2023 Bain Capital Specialty Finance Inc. (BCSF) is expected to report $0.57...
Applied Molecular Transport Inc. (AMTI) is expected to report $-0.5 for Q3 2023
2023-11-01 00:36:04 ET Summary Merger arbitrage spreads are wide. A number of opportunities with spreads from 10% to 137%. A review of the most interesting merger arb setups. Merger arbitrage is an event-driven investment strategy centered around betting on the succe...
2023-09-21 10:22:47 ET DENVER, Colo., Sept 21, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; Near Intelligence (NASDAQ:NIR), Splunk (NASDAQ:SPLK), Murphy Canyon Acquisition (NASDAQ:MURF), Tradeup Acquis...
Combined company will operate as Cyclo Therapeutics with primary focus on advancing Trappsol ® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 (NPC1) At closing combined Company will have approximately $13.7 million cash on hand to fund operations into 2H 2024 ...
2023-08-15 10:30:56 ET Applied Molecular Transport press release ( NASDAQ: AMTI ): Q2 GAAP EPS of -$0.44. Cash and cash equivalents. As of June 30, 2023, cash and cash equivalents were $22.5 million. For further details see: Applied Molecular Transport GAAP E...
Currently Pursuing Strategic Alternatives, with MTS Health Partners, L.P. Advising the Company Cash and Cash Equivalents of $22.5 million, as of June 30, 2023 SOUTH SAN FRANCISCO, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT)...
News, Short Squeeze, Breakout and More Instantly...
Applied Molecular Transport Inc. Company Name:
AMTI Stock Symbol:
NASDAQ Market:
Applied Molecular Transport Inc. Website:
Combined company operating as Cyclo Therapeutics with primary focus on advancing Trappsol ® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 (NPC1) Cash runway extended into 2H 2024 with approximately $11.0 million cash on hand to fund operations Cyclo ...
Company Entered into Definitive Merger Agreement with Cyclo Therapeutics Cash and Cash Equivalents of $18.1 million, as of September 30, 2023 SOUTH SAN FRANCISCO, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a biopharmaceut...
CGG ADR (CGGYY) is expected to report for quarter end 2023-09-30 ATI Physical Therapy Inc. Class A (ATIP) is expected to report $-4.08 for Q3 2023 Riot Platforms Inc. (RIOT) is expected to report $-0.29 for Q3 2023 Bain Capital Specialty Finance Inc. (BCSF) is expected to report $0.57...